media – Page 419 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Janssen inks inflammatory disease collaboration with Mestag Therapeutics

Janssen, the pharma division of Johnson & Johnson, has entered an agreement with Cambridge, UK-based Mestag Therapeutics to research and develop novel fibroblast targets for the treatment of inflammatory disease. The collaboration will utilise Mestag’s specialist fibroblast subpopulation biology platform, as well as the biotech’s ‘state-of-the-art’ data analytics in a bid to identify novel therapeutic targets. Under the terms of the agreement, Mestag will grant Janssen an option to an exclusive license to develop and commercialise therapeutics directed against up to two targets resulting from the collaboration. In exchange, Janssen will pay Mestag option fees, milestone payments and royalties – however, the detailed financial terms of the agreement were not disclosed by the companies. Also, as part of the collaboration, Janssen Research & Development’s global immunology therapeutic head David Lee will join Mestag’s scientific advisory committee. “Mestag’s vision is to leverage our unique fibroblast biology platform and state-of-the-art data analytics ...
- Source: drugdu
- 250
- May 19, 2021
Janssen
Novo Nordisk’s weight loss drug semaglutide found to improve wellbeing

New results from a Phase IIIa study have demonstrated that Novo Nordisk’s weight loss drug semaglutide improved physical function and wellbeing among people with obesity. The STEP 1 trial demonstrated benefits for people with obesity treated with semaglutide 2.4mg ‘beyond weight loss’, Novo said in a statement. Over a 68-week period, treatment with once-weekly semaglutide 2.4mg was associated with greater improvements for all weight- and health-related quality of life scores in people with obesity or overweight in comparison to placebo. This included improved wellbeing, with 43.8% of patients treated with Novo’s drug achieving a clinically meaningful improvement in total weight-related quality of life score at week 68. On top of that, 51.2% of participants treated with semaglutide 2.4mg in the trial had an increased weight-related physical function score, reflecting improvements in the ability to perform daily activities. In addition, patients treated with semaglutide 2.4mg ‘simultaneously’ experienced significant weight loss of ...
- Source: drugdu
- 460
- May 17, 2021
weight loss drug
EC clears GSK’s Benlysta for lupus nephritis

The European Commission approved expanded use of GlaxoSmithKline’s intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis (LN). The drug is already on the market to treat systemic lupus erythematosus (SLE); this latest approval now provides physicians and patients in Europe with the first and only biologic treatment specifically designed to work in lupus and LN. “Active lupus nephritis, which causes inflammation in the kidneys, is one of the most serious consequences of systemic lupus erythematosus and occurs in more than 1 million patients worldwide,” noted Dr Hal Barron, GSK’s chief scientific officer and president R&D. “Benlysta is the first biologic approved to treat lupus and lupus nephritis, representing a significant new treatment option for patients and physicians across Europe dealing with this complex autoimmune disease.” The drug’s marketing submission was based on data from the BLISS-LN (Efficacy and Safety of Belimumab ...
- Source: drugdu
- 498
- May 10, 2021
GSK
Alchemab to collaborate with AstraZeneca on prostate cancer research

Cambridge-based biotech company Alchemab has announced a new collaboration with British pharma AstraZeneca (AZ), aiming to accelerate research for prostate cancer. As part of the collaboration, Alchemab and AZ will collaborate on a proof-of-concept study to improve understanding of the ‘fundamental biology’ of prostate cancer. Alchemab will utilise its novel drug discovery platform as a diagnostic tool through the identification of disease biomarkers, with the potential to inform the development of new antibody-based medications. Under the agreement, Alchemab will sequence and explore antibody repertoires in patient samples gathered from a clinical trial of an undisclosed immuno-oncology agent within AZ’s pipeline. Alchemab may also be able to identify antibody sequence patterns that could be used as biomarkers for early detection and patient stratification by classifying patients into two groups – responders and non-responders. The overall purpose of the collaboration is to identify novel and disease-relevant antibodies which may generate therapeutic insights into ...
- Source: drugdu
- 373
- May 7, 2021
AstraZeneca
RPS makes new recommendations for pharmacist independent prescribers

The Royal Pharmaceutical Society of Great Britain (RPS) has made new recommendations to increase the use of pharmacist independent prescribers (PIP) in the UK. In a statement, RPS highlighted that the role of PIPs has become ‘increasingly’ important in delivering high-quality clinical care. The Society added that it wants to see increased use of PIPs in multi-disciplinary teams to expand patient access to care, as well as create capacity in the healthcare system and improve health outcomes. The three core recommendations call on governments and healthcare organisations to proactively: establish the right infrastructure, systems and tools to enable patients to benefit from PIPs develop the PIP workforce required to work routinely as part of multi-professional teams in all health care settings provide ongoing professional development for PIPs as well as expand their role in teaching and peer support. “Non-medical prescribing was introduced in the UK some 30 years ago, but ...
- Source: drugdu
- 201
- April 28, 2021
pharmacist independent prescribers
Positive topline results for nirsevimab in RSV

Sanofi and AstraZeneca’s (AZ) monoclonal antibody (mAb) nirsevimab reached its primary endpoint in a Phase III trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants. Nirsevimab, an investigational extended half-life mAb is designed to protect infants entering their first RSV season, when they are at a higher risk for developing severe RSV disease. In the Phase III MELODY trial, nirsevimab reduced lower respiratory tract infections (LRTI) requiring medical attention due to RSV in healthy preterm and term infants. There were no clinically meaningful differences observed in the safety results between the nirsevimab and placebo groups, with the overall safety profile for nirsevimab in the trial remaining consistent with previously reported results. “Respiratory syncytial virus is the leading cause of hospitalisations in all infants,” said Jean-François Toussaint, global head of research and development, Sanofi Pasteur. “In fact, most hospitalisations occur in otherwise healthy infants born at term. It’s ...
- Source: drugdu
- 115
- April 26, 2021
nirsevimab
New report suggests the gender pay gap for doctors increased during pandemic

A new report suggests that the gender pay gap for doctors has increased during the pandemic, with female doctors found to be disproportionately affected by falling earnings. The Medscape UK Doctors’ Salary and Sanctification Survey 2021, conducted between 10 November 2020 to 16 February 2021, includes responses from over 1,000 doctors in England, Scotland, Wales and Norther Ireland. This includes doctors from a range of specialities, with 73% working in the NHS, 23% working in both the NHS and private sector and 4% in the private sector only. The report considers changes in doctors’ average salaries since Medscape’s last salary and satisfaction survey released in 2019. It found that overall, 29% of UK doctors reported a drop in income, compared with 17% in 2019. Some doctors attributed the decrease in earnings to COVID-19 ‘multiple times’, while others cited different reasons. The report also suggests that women have suffered a greater ...
- Source: drugdu
- 264
- April 23, 2021
pandemic
GW Pharma’s Epidyolex scores new EU indication

GW Pharmaceuticals’ Epidyolex has received approval from the European Commission (EC) for the treatment of seizures associated with tuberous sclerosis complex (TSC) – its third indication in Europe. Specifically, Epidyolex (cannabidiol) has been approved as an adjunctive treatment of seizures associated with TSC for patients aged two years and older. TSC is a rare genetic condition that causes mostly benign tumours to grow in vital organs including the brain, skin, heart, eyes, kidney and lungs. The condition is typically diagnosed in childhood and the most common neurological feature in TSC is epilepsy. It is also associated with an increased risk of autism and intellectual disability, although the severity of the condition can vary widely. The EC approval is based on data from a Phase III trial evaluating Epidyolex for the treatment of seizures associated with TSC. This study hit its primary endpoint of reduction in seizure frequency, with seizure reduction ...
- Source: drugdu
- 234
- April 21, 2021
Epidyolex
Real-world data suggests Sputnik V vaccine is 97.6% effective, says RDIF

New real-world data has suggested that Russia’s Sputnik V vaccine is 97.6% effective against COVID-19, the Gamaleya Institute and the Russian Direct Investment Fund (RDIF) announced yesterday. The new efficacy rate is based on the analysis of data from 3.8 million Russians vaccinated with both components of Sputnik V from between 5 December 2020 and 31 March 2021. In a statement, the RDIF said the Ministry of Health of Russia maintains a register of those who have been vaccinated, as well as citizens who have been infected with COVID-19. According to the data, the infection rate starting from the 35th day from the date of the first injection was 0.027%. The incidence among the unvaccinated adult population was found to be 1.1% for a comparable period starting from the 35th day after the launch of the mass-scale vaccination in Russia. The data and calculations used to determine the vaccine’s efficacy will be ...
- Source: drugdu
- 228
- April 20, 2021
Sputnik V
Gilead’s Trodelvy scores accelerated approval in advanced bladder cancer

Gilead’s antibody drug conjugate (ADC) Trodelvy has received an accelerated approval from the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic urothelial cancer (UC), the most common form of bladder cancer. The approval covers the use of Trodelvy (sacituzumab govitecan-hziy) in patients with advanced UC who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor. Trodelvy was approved on the basis of results from Gilead’s Phase II TROPHY study, which evaluated the drug as monotherapy or as a combination therapy in patients with metastatic UC after progression on a platinum-based chemotherapy and PD-1/L1 inhibitor. In 112 patients who were evaluable for efficacy, 27.7% of those who were treated with Trodelvy responded to treatment, with 5.4% experiencing a complete response and 22.3% experiencing a partial response. The study also found a median duration of response of 7.2 months for those treated ...
- Source: drugdu
- 180
- April 15, 2021
bladder cancer

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.